Skip to content

EveryLife Foundation comments to Food and Drug Administration (FDA) on setting recommendations for diversity plans that aim to increase clinical trial diversity

Share this page

Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials: Guidance for Industry

Related Articles